novoeight
novo nordisk pharmaceuticals ltd - turoctocog alfa 2000 [iu]; - injection with diluent - 2000 iu - active: turoctocog alfa 2000 [iu] excipient: calcium chloride dihydrate histidine hydrochloric acid methionine polysorbate 80 sodium chloride sodium hydroxide sucrose sodium chloride - for the treatment and prophylaxis of bleeding episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings.
novoeight
novo nordisk pharmaceuticals ltd - turoctocog alfa 250 [iu]; - injection with diluent - 250 iu - active: turoctocog alfa 250 [iu] excipient: calcium chloride dihydrate histidine hydrochloric acid methionine polysorbate 80 sodium chloride sodium hydroxide sucrose sodium chloride - for the treatment and prophylaxis of bleeding episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings.
novoeight
novo nordisk pharmaceuticals ltd - turoctocog alfa 3000 [iu]; - injection with diluent - 3000 iu - active: turoctocog alfa 3000 [iu] excipient: calcium chloride dihydrate histidine hydrochloric acid methionine polysorbate 80 sodium chloride sodium hydroxide sucrose sodium chloride - for the treatment and prophylaxis of bleeding episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings.
novoeight
novo nordisk pharmaceuticals ltd - turoctocog alfa 500 [iu]; - injection with diluent - 500 iu - active: turoctocog alfa 500 [iu] excipient: calcium chloride dihydrate histidine hydrochloric acid methionine polysorbate 80 sodium chloride sodium hydroxide sucrose sodium chloride - for the treatment and prophylaxis of bleeding episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings.
saxenda liraglutide (rys) 6mg/ml solution for injection, pre-filled pen
novo nordisk pharmaceuticals pty ltd - liraglutide, quantity: 6 mg/ml - injection, solution - excipient ingredients: phenol; hydrochloric acid; water for injections; propylene glycol; dibasic sodium phosphate dihydrate; sodium hydroxide - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of:,- greater than or equal to 30 kg/m2 (obese) or,- greater than or equal to 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea.,treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.
levemir penfill insulin detemir (rys) 100 u/ml injection cartridge
novo nordisk pharmaceuticals pty ltd - insulin detemir, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; glycerol; dibasic sodium phosphate dihydrate; metacresol; hydrochloric acid; zinc acetate; water for injections; sodium hydroxide; sodium chloride - treatment of diabetes mellitus. (see 'pharmacology' and 'clinical trials.')
vagifem low estradiol 10 ug (as hemihydrate) modified release pessary blister pack
novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 10.3 microgram (equivalent: estradiol, qty 10 microgram) - pessary, modified release - excipient ingredients: macrogol 6000; magnesium stearate; lactose monohydrate; hypromellose; maize starch - vagifem low is indicated for the treatment of atrophic vaginitis due to oestrogen deficiency. vagifem low is not intended for children or males.
ryzodeg 70/30 penfill 70% insulin degludec (rys) / 30% insulin aspart (rys) 100 u/ml solution for injection cartridge
novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 180 nmol/ml; insulin degludec, quantity: 420 nmol/ml - injection, solution - excipient ingredients: zinc acetate; phenol; hydrochloric acid; sodium chloride; metacresol; water for injections; sodium hydroxide; glycerol - for use in diabetes mellitus in patients aged 6 years and older.
medicine administration kit, percutaneous, non-medicated, single-use
novo nordisk pharmaceuticals pty ltd - 45158 - medicine administration kit, percutaneous, non-medicated, single-use - the kit is intended for the injection of novo nordisk factor products.
actrapid
novo nordisk pharmaceuticals ltd - neutral insulin, human, pyr 100 iu/ml; - solution for injection - 100 iu/ml - active: neutral insulin, human, pyr 100 iu/ml excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc - treatment of diabetes mellitus. furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.